Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
The department performs basic research in cancer immunology and virology and develops new therapeutic strategies based on novel mechanistic insights. Cancer immunology is now one of the most exciting and important areas of investigation in the cancer field. Recent clinical trials …
The magnitude and durability of responses to immunotherapies in patients with diverse types of cancer are unprecedented in oncology. Dana-Farber has a long history of excellence in this field, and our immunology investigators have made important contributions to theseadvances …
Cancer immunology is an important part of the fabric of the Institute, and our mission is to serve as an intellectual center for cancer immunology efforts across the Institute and the Harvard Medical School community. Many investigators from other fields …
We closely collaborate with our clinical colleagues, aiming for a seamless transition from basic discovery to clinical translation. This sense of community is fostered at monthly faculty meetings in which all investigators interested in immunology are invited to participate, including …
We emphasize development and implementation of cutting-edge technologies that enhance our ability to study immune responses in animal models and patients. An example is the mass cytometry technology (CyTOF) which enables simultaneous analysis of >30 intracellular and cell surface molecules …
Kai W. Wucherpfennig, MD, PhD
Harvey Cantor, MD
Stephanie Dougan, PhD
Alan N. Engelman, PhD
Gordon J. Freeman, PhD
Dana H. Gabuzda, MD
Michael Goldberg, PhD
W. Nicholas Haining, BM, BCh
Martin E. Hemler, PhD
Philip J. Kranzusch, PhD
Wayne A. Marasco, MD, PhD
Carl Novina, MD, PhD
Joseph G. Sodroski, MD
Baochun Zhang, MD, PhD
All therapeutic advances in cancer immunology are based on our growing understanding of fundamental immunological mechanisms. We approach immunology as a complex system in which many cell populations activate and regulate each other. We believe that the complexity of the … read more ›
Our department is developing novel approaches for immunotherapy, and we closely collaborate with our clinical colleagues to advance important discoveries to clinical trials. The Wucherpfennig Lab has developed a novel approach for systematic discovery of negative regulators of T cell function … read more ›
HIV infects a critical population of immune cells (CD4 T cells), resulting in an immunodeficiency syndrome that predisposes to opportunistic infections and cancer. A shared interest by HIV and cancer immunology investigators is the development of vaccines that stimulate strong … read more ›
At monthly faculty meetings, basic and clinical immunologists discuss ongoing research in their labs in order to foster translation of immunological principles into clinical immunotherapy trials. Immunologists in other departments are part of our vibrant immunology community and contribute expertise … read more ›
Immune response to flu vaccine linked to recipients' ethnic background, say researchers
How well a flu shot protects you from the virus can depend on your ethnic background and other inherited factors, report Dana-Farber scientists led by cancer immunologist and virologist Wayne Marasco, MD, PhD … full story
Discovery opens door to new strategy for cancer immunotherapy
New research by Dana-Farber scientists raises the prospect of cancer therapy that turns a tumor's best friends in the immune system into its gravest enemies. As reported in the journal Science, investigators uncovered a mechanism that allows key immune system cells to … full story
Dana-Farber researcher wins NIH Pioneer award for 'bold and innovative' research project
Carl Novina, MD, PhD, a researcher in the Department of Cancer Immunology and Virology at Dana-Farber Cancer Institute, is one of 10 scientists chosen to receive a 2014 National Institutes of Health Pioneer Award, which funds bold and innovative … full story
Turning back the clock on cancer
Preventing cancer, or even reversing its earliest stages, would be hugely preferable to treating more advanced cases. Now, Dana-Farber researcher Michael Goldberg, PhD, has contributed to research that demonstrates one way this might work. “Conventional wisdom holds that we must … full story
In vivo discovery of targets for cancer immunotherapy
Therapeutic targets are typically identified using in vitro approaches, but the complex interactions of migratory immune cells with many other cell populations are very difficult to model using in vitro systems. The Wucherpfennig lab developed an in vivo shRNA screening … full story
Watch as Kai Wucherpfennig, MD, PhD, and Carl Novina, MD, PhD, describe the exciting projects and therapeutic benefits of the Department’s basic research in immunology and immunotherapy.
Learn about our opportunities for graduate students, postdoctoral fellows, clinical fellows, and junior faculty
Join our team ›
Browse all career opportunities ›
Our mailing address is 450 Brookline Avenue, SM-0722, Boston, MA 02215.
To contact us, call or email Alison Angel at 617-632-3328, firstname.lastname@example.org.
To learn more about the many ways you can support Dana-Farber’s research initiatives with a philanthropic gift, please contact Rebecca Freedman at 617-632-4215 or email@example.com.